Related Experiment Video
Updated: Feb 5, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma
Alexandra Lacey1, Erik Hedrick1, Yating Cheng1
1Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas.
Abstract:
Alveolar rhabdomyosarcoma (ARMS) patients have a poor prognosis, and this is primarily due to overexpression of the oncogenic fusion protein PAX3-FOXO1. Results of RNA-sequencing studies show that PAX3-FOXO1 represses expression of interleukin-24 (IL24), and these two genes are inversely expressed in patient tumors. PAX3-FOXO1 also regulates histone deacetylase 5 (HDAC5) in ARMS cells, and results of RNA interference studies confirmed that PAX3-FOXO1-mediated repression of IL24 is HDAC5-dependent. Knockdown of PAX3-FOXO1 decreases ARMS cell proliferation, survival, and migration, and we also observed similar responses in cells after overexpression of IL24, consistent with results reported for this tumor suppressor-like cytokine in other solid tumors. We also observed in double knockdown studies that the inhibition of ARMS cell proliferation, survival, and migration after knockdown of PAX3-FOXO1 was significantly (>75%) reversed by knockdown of IL24. Adenoviral-expressed IL24 was directly injected into ARMS tumors in athymic nude mice, and this resulted in decreased tumor growth and weight. Because adenoviral IL24 has already successfully undergone phase I in clinical trials, this represents an alternative approach (alone and/or combination) for treating ARMS patients who currently undergo cytotoxic drug therapies.
Insights
Alveolar rhabdomyosarcoma (ARMS) is driven by PAX3-FOXO1, which suppresses the tumor suppressor IL24. Restoring IL24 inhibits ARMS growth, offering a potential new therapy for patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Alveolar rhabdomyosarcoma (ARMS) is characterized by poor prognosis, largely due to the oncogenic fusion protein PAX3-FOXO1.
- PAX3-FOXO1 overexpression is linked to repressed interleukin-24 (IL24) expression in ARMS tumors, showing an inverse relationship.
Purpose of the Study:
- To investigate the regulatory relationship between PAX3-FOXO1 and IL24 in ARMS.
- To evaluate the therapeutic potential of IL24 in ARMS models.
Main Methods:
- RNA-sequencing and RNA interference studies were employed to analyze gene expression and functional impacts.
- In vivo studies involved direct injection of adenoviral-expressed IL24 into ARMS tumors in mice.
Main Results:
- PAX3-FOXO1 represses IL24 expression in an HDAC5-dependent manner.
- Knockdown of PAX3-FOXO1 or overexpression of IL24 inhibited ARMS cell proliferation, survival, and migration.
- IL24 restoration significantly reversed the effects of PAX3-FOXO1 knockdown.
- Adenoviral IL24 administration reduced tumor growth and weight in vivo.
Conclusions:
- IL24 acts as a tumor suppressor in ARMS and its restoration can inhibit tumor progression.
- Adenoviral IL24 represents a promising therapeutic strategy for ARMS, with potential for use alone or in combination therapies.
Related Concept Videos
Holter Monitor: 24-Hour Monitoring
Gene Therapy
Group Therapy
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...

